Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
HCA vs THC vs CYH vs UHS vs ENSG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
HCA vs THC vs CYH vs UHS vs ENSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $95.86B | $16.37B | $397M | $10.35B | $10.28B |
| Revenue (TTM) | $75.60B | $21.45B | $21.48B | $17.76B | $5.27B |
| Net Income (TTM) | $6.78B | $1.70B | $-88M | $1.52B | $363M |
| Gross Margin | 41.5% | 42.8% | 53.7% | 67.6% | 15.2% |
| Operating Margin | 15.8% | 16.1% | -39.8% | 11.5% | 8.5% |
| Forward P/E | 14.2x | 10.5x | 0.7x | 7.1x | 23.4x |
| Total Debt | $50.20B | $13.17B | $11.58B | $5.51B | $4.15B |
| Cash & Equiv. | $1.04B | $2.88B | $260M | $138M | $504M |
HCA vs THC vs CYH vs UHS vs ENSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| HCA Healthcare, Inc. (HCA) | 100 | 401.1 | +301.1% |
| Tenet Healthcare Co… (THC) | 100 | 859.0 | +759.0% |
| Community Health Sy… (CYH) | 100 | 89.5 | -10.5% |
| Universal Health Se… (UHS) | 100 | 156.9 | +56.9% |
| The Ensign Group, I… (ENSG) | 100 | 402.4 | +302.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HCA vs THC vs CYH vs UHS vs ENSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Beta 0.29, yield 0.7%, current ratio 0.83x
- 9.0% margin vs CYH's -0.4%
- Beta 0.29 vs CYH's 1.60
THC is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 491.5% 10Y total return vs ENSG's 7.6%
- PEG 0.32 vs ENSG's 1.70
CYH ranks third and is worth considering specifically for value.
- Lower P/E (0.7x vs 23.4x)
UHS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.60, Low D/E 74.3%, current ratio 1.05x
ENSG is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- 18.7% revenue growth vs CYH's -1.2%
- +33.7% vs UHS's -6.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% revenue growth vs CYH's -1.2% | |
| Value | Lower P/E (0.7x vs 23.4x) | |
| Quality / Margins | 9.0% margin vs CYH's -0.4% | |
| Stability / Safety | Beta 0.29 vs CYH's 1.60 | |
| Dividends | 0.7% yield, 5-year raise streak, vs ENSG's 0.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +33.7% vs UHS's -6.7% | |
| Efficiency (ROA) | 11.3% ROA vs CYH's -0.7%, ROIC 19.9% vs -70.1% |
HCA vs THC vs CYH vs UHS vs ENSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
HCA vs THC vs CYH vs UHS vs ENSG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
THC leads in 1 of 6 categories
HCA leads 1 • CYH leads 0 • UHS leads 0 • ENSG leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
THC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 14.3x ENSG's $5.3B. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to CYH's -0.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $75.6B | $21.5B | $21.5B | $17.8B | $5.3B |
| EBITDAEarnings before interest/tax | $15.5B | $4.3B | -$7.8B | $2.7B | $558M |
| Net IncomeAfter-tax profit | $6.8B | $1.7B | -$88M | $1.5B | $363M |
| Free Cash FlowCash after capex | $7.7B | $3.3B | -$200M | $894M | $406M |
| Gross MarginGross profit ÷ Revenue | +41.5% | +42.8% | +53.7% | +67.6% | +15.2% |
| Operating MarginEBIT ÷ Revenue | +15.8% | +16.1% | -39.8% | +11.5% | +8.5% |
| Net MarginNet income ÷ Revenue | +9.0% | +7.9% | -0.4% | +8.6% | +6.9% |
| FCF MarginFCF ÷ Revenue | +10.2% | +15.6% | -0.9% | +5.0% | +7.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.7% | +2.8% | +2.8% | +9.6% | +18.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +44.6% | +87.6% | -45.2% | +17.7% | +21.9% |
Valuation Metrics
Evenly matched — CYH and UHS each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 0.7x trailing earnings, CYH trades at a 98% valuation discount to ENSG's 30.1x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.37x vs ENSG's 2.18x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $95.9B | $16.4B | $397M | $10.4B | $10.3B |
| Enterprise ValueMkt cap + debt − cash | $145.0B | $26.7B | $11.7B | $15.7B | $13.9B |
| Trailing P/EPrice ÷ TTM EPS | 15.11x | 12.07x | 0.75x | 7.16x | 30.13x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.18x | 10.53x | — | 7.08x | 23.41x |
| PEG RatioP/E ÷ EPS growth rate | 0.72x | 0.37x | — | 0.45x | 2.18x |
| EV / EBITDAEnterprise value multiple | 9.36x | 6.20x | — | 6.02x | 25.88x |
| Price / SalesMarket cap ÷ Revenue | 1.27x | 0.77x | 0.03x | 0.60x | 2.03x |
| Price / BookPrice ÷ Book value/share | — | 1.89x | — | 1.44x | 4.64x |
| Price / FCFMarket cap ÷ FCF | 12.46x | 6.47x | 1.91x | 12.19x | 27.72x |
Profitability & Efficiency
HCA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $17 for ENSG. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs ENSG's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +19.6% | — | +20.7% | +16.6% |
| ROA (TTM)Return on assets | +11.3% | +5.7% | -0.7% | +9.8% | +6.8% |
| ROICReturn on invested capital | +19.9% | +13.2% | -70.1% | +12.3% | +7.0% |
| ROCEReturn on capital employed | +27.0% | +13.8% | -87.3% | +16.0% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | — | 1.47x | — | 0.74x | 1.86x |
| Net DebtTotal debt minus cash | $49.2B | $10.3B | $11.3B | $5.4B | $3.7B |
| Cash & Equiv.Liquid assets | $1.0B | $2.9B | $260M | $138M | $504M |
| Total DebtShort + long-term debt | $50.2B | $13.2B | $11.6B | $5.5B | $4.2B |
| Interest CoverageEBIT ÷ Interest expense | 5.37x | 4.28x | 4.89x | 10.92x | 88.33x |
Total Returns (Dividends Reinvested)
Evenly matched — THC and ENSG each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,145 today (with dividends reinvested), compared to $2,038 for CYH. Over the past 12 months, ENSG leads with a +33.7% total return vs UHS's -6.7%. The 3-year compound annual growth rate (CAGR) favors THC at 39.2% vs CYH's -8.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -8.7% | -6.3% | -9.0% | -24.7% | +1.2% |
| 1-Year ReturnPast 12 months | +23.6% | +25.4% | -0.7% | -6.7% | +33.7% |
| 3-Year ReturnCumulative with dividends | +57.1% | +169.5% | -23.0% | +17.5% | +91.1% |
| 5-Year ReturnCumulative with dividends | +112.3% | +191.5% | -79.6% | +10.3% | +105.2% |
| 10-Year ReturnCumulative with dividends | +452.6% | +491.5% | -81.6% | +28.4% | +760.4% |
| CAGR (3Y)Annualised 3-year return | +16.3% | +39.2% | -8.3% | +5.5% | +24.1% |
Risk & Volatility
Evenly matched — HCA and ENSG each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than CYH's 1.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ENSG currently trades 80.7% from its 52-week high vs CYH's 63.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.29x | 0.71x | 1.60x | 0.60x | 0.42x |
| 52-Week HighHighest price in past year | $556.52 | $247.21 | $4.47 | $246.33 | $218.00 |
| 52-Week LowLowest price in past year | $330.00 | $146.31 | $2.38 | $152.33 | $129.91 |
| % of 52W HighCurrent price vs 52-week peak | +77.0% | +75.6% | +63.1% | +67.1% | +80.7% |
| RSI (14)Momentum oscillator 0–100 | 29.2 | 44.6 | 45.2 | 35.7 | 28.6 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 1.2M | 1.7M | 779K | 348K |
Analyst Outlook
Evenly matched — HCA and ENSG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: HCA as "Buy", THC as "Buy", CYH as "Hold", UHS as "Hold", ENSG as "Buy". Consensus price targets imply 43.4% upside for THC (target: $268) vs 3.9% for CYH (target: $3). For income investors, HCA offers the higher dividend yield at 0.69% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | $527.45 | $268.00 | $2.93 | $231.50 | $222.33 |
| # AnalystsCovering analysts | 46 | 32 | 37 | 43 | 13 |
| Dividend YieldAnnual dividend ÷ price | +0.7% | — | — | +0.5% | +0.1% |
| Dividend StreakConsecutive years of raises | 5 | 0 | 2 | 1 | 12 |
| Dividend / ShareAnnual DPS | $2.94 | — | — | $0.80 | $0.24 |
| Buyback YieldShare repurchases ÷ mkt cap | +10.5% | +8.8% | +0.5% | +9.3% | +0.2% |
THC leads in 1 of 6 categories (Income & Cash Flow). HCA leads in 1 (Profitability & Efficiency). 4 tied.
HCA vs THC vs CYH vs UHS vs ENSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is HCA or THC or CYH or UHS or ENSG a better buy right now?
For growth investors, The Ensign Group, Inc.
(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus -1. 2% for Community Health Systems, Inc. (CYH). Community Health Systems, Inc. (CYH) offers the better valuation at 0. 7x trailing P/E, making it the more compelling value choice. Analysts rate HCA Healthcare, Inc. (HCA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HCA or THC or CYH or UHS or ENSG?
On trailing P/E, Community Health Systems, Inc.
(CYH) is the cheapest at 0. 7x versus The Ensign Group, Inc. at 30. 1x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 32x versus The Ensign Group, Inc. 's 1. 70x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — HCA or THC or CYH or UHS or ENSG?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +191.
5%, compared to -79. 6% for Community Health Systems, Inc. (CYH). Over 10 years, the gap is even starker: ENSG returned +760. 4% versus CYH's -81. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HCA or THC or CYH or UHS or ENSG?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Community Health Systems, Inc. 's 1. 60β — meaning CYH is approximately 460% more volatile than HCA relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — HCA or THC or CYH or UHS or ENSG?
By revenue growth (latest reported year), The Ensign Group, Inc.
(ENSG) is pulling ahead at 18. 7% versus -1. 2% for Community Health Systems, Inc. (CYH). On earnings-per-share growth, the picture is similar: Community Health Systems, Inc. grew EPS 196. 7% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HCA or THC or CYH or UHS or ENSG?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus 4. 1% for Community Health Systems, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus -79. 4% for CYH. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HCA or THC or CYH or UHS or ENSG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 32x versus The Ensign Group, Inc. 's 1. 70x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 1x forward P/E versus 23. 4x for The Ensign Group, Inc. — 16. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 43. 4% to $268. 00.
08Which pays a better dividend — HCA or THC or CYH or UHS or ENSG?
In this comparison, HCA (0.
7% yield), UHS (0. 5% yield), ENSG (0. 1% yield) pay a dividend. THC, CYH do not pay a meaningful dividend and should not be held primarily for income.
09Is HCA or THC or CYH or UHS or ENSG better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +452. 6% 10Y return). Community Health Systems, Inc. (CYH) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCA: +452. 6%, CYH: -81. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HCA and THC and CYH and UHS and ENSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: HCA is a mid-cap deep-value stock; THC is a mid-cap deep-value stock; CYH is a small-cap deep-value stock; UHS is a mid-cap deep-value stock; ENSG is a mid-cap high-growth stock. HCA pays a dividend while THC, CYH, UHS, ENSG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.